Related Experiment Video

Updated: Jun 22, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer

C Papewalis1, M Wuttke, S Schinner

  • 1Endocrine Cancer Center, Department of Endocrinology, Diabetes and Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany. claudia.papewalis@uni-duesseldorf.de

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|June 11, 2009
PubMed

Insights

RAD001 (everolimus) demonstrated dose-dependent growth inhibition in some anaplastic thyroid cancer (ATC) cell lines by suppressing proliferation. This suggests potential clinical applications for mTOR-targeted therapy in specific ATC cases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Phosphatidylinositol-3-kinase (PI3K) signaling is frequently activated in thyroid follicular neoplasms.
  • Mammalian target of rapamycin (mTOR), a key downstream effector of PI3K, drives cell growth and proliferation.
  • mTOR is a potential therapeutic target for thyroid cancers, with rapamycin derivatives offering direct inhibition.

Purpose of the Study:

  • To investigate the efficacy of RAD001 (everolimus) in selectively inhibiting the proliferation of anaplastic thyroid cancer (ATC) cells.
  • To determine the dose-response relationship of RAD001 in various human ATC cell lines.
  • To assess the impact of RAD001 on proliferation markers in ATC cells.

Main Methods:

  • Treatment of five human ATC cell lines with varying concentrations of RAD001.
  • Assessment of cell growth inhibition (GI50) at different RAD001 concentrations.
  • Quantitative PCR analysis of Proliferating Cell Nuclear Antigen (PCNA) expression.

Main Results:

  • RAD001 induced dose-dependent growth inhibition in two out of five ATC cell lines at concentrations of 43.5 and 94.5 nM.
  • The remaining cell lines showed GI50 values ranging from 168 to 234 nM.
  • Quantitative PCR confirmed reduced PCNA expression in the responding ATC cell lines.

Conclusions:

  • RAD001 exhibits selective anti-proliferative effects in a subset of anaplastic thyroid cancer cell lines.
  • The observed growth inhibition and reduced PCNA expression suggest mTOR pathway modulation by RAD001.
  • These findings indicate a potential clinical utility for RAD001 in treating specific anaplastic thyroid cancer patients.

More Related Videos

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...